#USA #New York #Heart Failure #Axon Therapies #Satera Ablation

Axon Therapies Secures $32 Million to Revolutionize Heart Failure Treatments

Introduction

On September 25, 2025, Axon Therapies, a pioneering company in clinical-stage medical devices focused on innovative heart failure treatment, announced that it has successfully closed an oversubscribed Series A financing round, raising $32 million. This funding round was co-led by new backers Earlybird Venture Capital and Santé Ventures, alongside contributions from previous investor Deerfield Management and new entrants CD Capital and KOFA Healthcare. The capital raised will play a crucial role in propelling the company's next phase of clinical trials.

The Challenge of Heart Failure

Heart failure is a critical health issue affecting approximately 64 million individuals worldwide and resulting in over a million hospitalizations annually in the United States alone. Despite recent advancements in treatment methods, including pharmaceuticals and devices, many patients continue to experience symptoms, highlighting a significant gap in effective treatment options. Axon Therapies intends to fill this void with their innovative approach.

Innovative Treatment Approach

The funding will accelerate two double-blinded randomized feasibility studies related to heart failure treatment, targeting its root causes. The first study will confirm the effectiveness of their novel splanchnic ablation therapy, particularly for patients suffering from Heart Failure with Preserved Ejection Fraction (HFpEF). The second study will include multiple centers focusing on splanchnic ablation for patients diagnosed with Heart Failure with Reduced Ejection Fraction (HFrEF).

By isolating the overactivity present in the sympathetic nervous system— a pivotal factor that exacerbates heart failure—Axon Therapies aims to provide a much-needed solution. Their proprietary therapy method, Splanchnic Ablation for Volume Management (SAVM), is designed to address the core physiological driver of heart failure without the need for implants. This strategy not only seeks to slow disease progression but also aims to enhance the quality of life for patients.

Leadership and Future Developments

In conjunction with the funding announcement, Dr. Zoar Engelman, a co-founder and the former Chief Scientific Officer of Axon, has been appointed the Chief Executive Officer. Dr. Engelman expressed the urgency of the situation, stating, "Heart failure is one of the leading causes of hospitalization and death worldwide, yet patients still face a lack of effective treatment options. This funding positions us to advance to pivotal trials and bring hope to patients who urgently need new solutions."

Establishing a European Presence

Axon Therapies has made a strategic decision to establish a new European headquarters, Axon Vascular Europe Ltd, in the UK. This location will provide a specialized hub aimed at accelerating clinical trial efforts and strategically preparing for future entry into Europe’s expansive heart failure market.

Dr. Engelman noted, "The opening of our new European headquarters will enhance our capabilities to address an unmet clinical need while bolstering our market position."

Investor Insights

Dr. John Yianni from Earlybird Venture Capital conveyed his confidence in Axon Therapies, emphasizing their clear vision of addressing critical healthcare needs and improving the lives of patients struggling with heart failure. Meanwhile, Dr. James Eadie from Santé Ventures highlighted the significant commercial potential of Axon's first-in-class technology, describing it as a lucrative asset for any leading cardiovascular organization.

Conclusion

Axon Therapies stands at the forefront of innovation in cardiac care with its dedicated approach to treating heart failure. As they progress with pivotal trials and expansion into the European market, their groundbreaking technology promises not only to transform patient outcomes but also aims to provide hope for millions affected by this debilitating condition. The investment solidifies Axon’s commitment to being a key player in the evolving landscape of medical technology solutions for heart failure.

To learn more about Axon Therapies, visit www.axontherapies.com.